Increases in antibiotic resistances in all genera of bacteria are a raising concern worldwide. The frequency of antimicrobial resistance in bacteria has increased in line with increasing usage of antimicrobial compounds.


pdf Download our brochure

The extensive use of antimicrobials in human medicine over the past 70 years has now led to a major threat to clinical practice due to a relentless rise in the number and types of microorganisms resistant to these medicines.

The aim of this project is to fight against Multi-Drug Resistant (MDR) Mycobacterium tuberculosis (M. tuberculosis) (TB) and Methicillin Resistant Staphylococcus aureus (MRSA), leading to serious diseases which usually require intensive care treatment with a long hospitalization. The project proposes nanotechnology solutions to this problem by the design, the preparation and the optimization of several nanoformulations of current antibiotics and novel antibacterial drugs.

The objectives to achieve within the 4 years of the NAREB project are : 1/ to select antibacterial molecules and design nanocarriers with strong antibacterial activity, 2/ to test in vitro and in vivo the best therapeutic combinations including innovative genomic and bioimaging approaches, 3/ to assess safety, regulatory and production (GLP/GMP) aspects for the most promising nanoformulations, and 4/ to establishing the Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations.

The World Health Organisation (WHO) has recognized antibiotic resistance as one of the three major threats to global health, and is predicting a forthcoming disaster due to the rapid, unchecked increase in antimicrobial resistance largely as a consequence of the paucity of new classes of antibacterials in development.

The development of effective and safe nanotherapy approaches is particularly relevant in the antibacterial field, where typically high dose levels of drug are administered.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.